<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939536</url>
  </required_header>
  <id_info>
    <org_study_id>US/05/003</org_study_id>
    <nct_id>NCT00939536</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions</brief_title>
  <official_title>Studies in Fasted Healthy, Normal Subjects to Compare the Single Dose Bio-availability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Objective:

             -  To compare the rate and extent of absorption of Zolpidem Tablets 10mg: Test
                Product: Zolpidem Tablets 10mg manufactured by Torrent Pharmaceuticals Limited,
                India Reference Product: Ambien® Tablets 10 mg (Reference Listed Drug) manufactured
                by Sanofi- Synthelabo Inc. under fasting conditions in 24 healthy, adult, human
                subjects.

        -  Study Design:

             -  Open label, randomized, two-period, two-treatment, two-sequence single dose
                crossover design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two-period, two-treatment, two-sequence single dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The maximum or peak concentration that the drug reaches in the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Torrent's Zolpidem Tartrate Tablets 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sanofi-Synthelabo's Ambien® 10 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem Tartrate Tablets 10 mg</intervention_name>
    <arm_group_label>Torrent's Zolpidem Tartrate Tablets 10 mg</arm_group_label>
    <arm_group_label>Sanofi-Synthelabo's Ambien® 10 mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects in the range of 18 - 45 years of age.

          2. Body weight within ± 15% of ideal weight as related to height and body frame according
             to Life Insurance Corporation (LIC) Chart. (Appendix A)

          3. Subjects with normal findings as determined by baseline history, physical examination
             and vital signs (blood pressure, pulse rate, respiration rate and body temperature)

          4. Subjects with normal findings as determined by hematological tests, serum chemistry,
             urine analysis, ECG and X-ray.

          5. Willingness to follow the protocol requirement as evidenced by written, informed
             consent.

          6. Agreeing to, not using any medication (prescription and over the counter), including
             vitamins and minerals for 15 days prior to study and during the course of the study.

          7. No history or presence of significant alcoholism or drug abuse in the past one year.

          8. Non-smokers, ex smokers and light smokers will be included. &quot;Light smokers are defined
             as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely
             stopped smoking for at least 3 months.

        Exclusion Criteria:

          1. Requiring medication for any ailment including enzyme-modifying drugs Use of any drugs
             known to induce or inhibit hepatic drug metabolism (e.g.s, inducers: barbiturates,
             carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors: SSRIs, cimetidine,
             diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones,
             antihistamines) within 30 days prior to administration of the study medication.

          2. Any medical or surgical conditions, which might significantly interfere with the
             functioning of gastrointestinal tract, blood-forming organs etc.

          3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
             metabolic diseases.

          4. History of psychiatric disorder or history of suicide attempt.

          5. Participation in a clinical drug study or bioequivalence study 90 days prior to
             present study.

          6. History of malignancy or other serious diseases.

          7. Refusal to abstain from food for ten (10) hours prior to study drug administration the
             day of each study period and for four (4) additional hours each, post dose.

          8. Refusal to abstain from water for one (1) hour prior to study drug administration the
             day of each study period and for two (2) additional hour, post dosing.

          9. Any contraindication to blood sampling.

         10. Refusal to abstain from smoking or consumption of tobacco products 24 hours before
             dosing until last sample collection of each period. Habituation of tobacco
             necessitating uninterrupted tobacco consumption.

         11. Use of xanthine-containing beverages or food for 48 hours prior to each drug dose.

         12. Blood donation 90 days prior to the commencement of the study.

         13. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.

         14. Known history of allergic reactions to zolpidem or other related drugs.

         15. History of drug abuse in the past one year.

         16. Use of prescription medication within 14 days prior to administration of study
             medication or over the counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 2 weeks prior to administration of study medication,
             except for topical products without systemic absorption.

         17. Pregnant and lactating women.

               -  At the time of screening, prior to enrollment, presence of pregnancy will be
                  confirmed by urine pregnancy test.

               -  Female subjects not confirming to using birth control measures, from the date of
                  screening till the completion of the second period of the study. Abstinence,
                  barrier methods (condom, diaphragm, etc.) are acceptable. Use of hormonal
                  contraceptives either oral or implants will not be acceptable.

         18. Female subjects whose menstruation cycle coincides with the study periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Accutest Research Laboratories Pvt. Ltd.</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>July 22, 2009</results_first_submitted>
  <results_first_submitted_qc>August 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2013</results_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>healthy, normal subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Torrent's Zolpidem First, Then Ambien</title>
          <description>For period one - on the morning of Day 1 subjects received Torrent's Zolpidem 10 mg.
Followed by a 7 day washout period.
For period two - on the morning of Day 1 subjects received the reference formulation, Ambien 10 mg.</description>
        </group>
        <group group_id="P2">
          <title>Ambien First, Then Torrent's Zolpidem</title>
          <description>For period one - on the morning of Day 1 subjects received the reference formulation, Ambien 10 mg
Followed by a 7 day washout period.
For period two - on the morning of Day 1 subjects received the test formulation, Torrent's Zolpidem 10 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Active Comparator</title>
          <description>Ambien® 10mg tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.7"/>
                    <measurement group_id="B2" value="28.2" spread="6.7"/>
                    <measurement group_id="B3" value="28.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The maximum or peak concentration that the drug reaches in the plasma</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The maximum or peak concentration that the drug reaches in the plasma</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.69" spread="57.05"/>
                    <measurement group_id="O2" value="172.64" spread="72.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.31" spread="399.17"/>
                    <measurement group_id="O2" value="717.71" spread="401.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="778.16" spread="418.74"/>
                    <measurement group_id="O2" value="741.65" spread="415.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator</title>
          <description>Ambien® 10mg tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>regurgitation of water content</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>giddiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kedar Joshi</name_or_title>
      <organization>Accutest Research Laboratories Pvt. Ltd.</organization>
      <phone>+91 22 27780718</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

